We take a look at India’s recovery rate, which is close to crossing 50%, and analyse why that number is important and what it shows about how the disease is affecting the population even as each new day seems to bring a new 24-hour high in cases recorded. Hydroxychloroquine is also back in the news after a study, published in the reputed journal Lancet about its adverse side-effects, reportedly used data supplied by a dubious U.S.-based data analytics company called Surgisphere. We discuss the potential ramifications. Guest: Jacob Koshy, Deputy Science Editor, The Hindu. Write to us with comments and feedback at socmed4@thehindu.co.in
Learn more about your ad choices. Visit megaphone.fm/adchoices
In Focus by The Hindu